Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib

Chromosome rearrangement involving anaplastic lymphoma kinase (ALK) has been identified in 3-5% NSCLC patients1, and ALK rearrangements have been defined as a molecular subset of NSCLC. Since the first report of echinoderm microtubule-associated like 4 (EML4) –ALK fusion in 20072, more than 90 fusion partners of the ALK gene have been identified in NSCLC3. PROFILE 1014 laid the first-line treatment status of crizotinib in patients with advanced ALK fusion-positive NSCLC4. However, emerging data suggest that clinical outcomes of crizotinib are vary from type to type of ALK fusion types.

Source: Lung Cancer - May 3, 2020 Category: Cancer & Oncology Authors: Yao Chen, Xiaochen Zhang, Qi Jiang, Bo Wang, Yina Wang Source Type: research